Literature DB >> 32205382

Progressive multifocal leukoencephalopathy following five lines of therapy and three autologous bone marrow transplants for multiple myeloma.

Kathryn Knight1, Siobhan Chien2, Ioannis Koutsavlis3, Victoria Campbell4.   

Abstract

A 59-year-old man, with a background of multiply relapsed myeloma, presented with a 3-week history of confusion, short-term memory impairment and behavioural changes. CT head showed bilateral white matter changes and numerous, large lytic lesions of the skull vault. MRI brain revealed multiple areas of hyperintensity on T2-weighted sequences which did not enhance (many of which showed diffusion restriction) unexpectedly bringing progressive multifocal leukoencephalopathy (PML) into the differential. Initial cerebrospinal fluid studies were largely unremarkable, aside from a mildly elevated protein; cultures were negative. PCR for the John Cunningham (JC) virus was positive. Considering the patient's medical history and rapidily progressive symptoms, a palliative approach was adopted, with the patient dying 14 days later. We present this case as an example of PML in a patient with multiple myeloma, highlighting the need to consider this diagnosis in an enlarging population of heavily treated, severely immunocompromised, patients. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  haematology (drugs and medicines); malignant disease and immunosuppression

Mesh:

Substances:

Year:  2020        PMID: 32205382      PMCID: PMC7103853          DOI: 10.1136/bcr-2019-233552

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

Review 1.  Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.

Authors:  Eugene O Major; Tarek A Yousry; David B Clifford
Journal:  Lancet Neurol       Date:  2018-05       Impact factor: 44.182

2.  Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy.

Authors:  L Fianchi; C Colosimo; A De Luca; A Pompucci; P Cattani; M T Voso; L M LaRocca; G Leone; L Pagano
Journal:  Bone Marrow Transplant       Date:  2010-03-01       Impact factor: 5.483

Review 3.  Sorting out the risks in progressive multifocal leukoencephalopathy.

Authors:  Leonard H Calabrese; Eamonn Molloy; Joseph Berger
Journal:  Nat Rev Rheumatol       Date:  2014-10-14       Impact factor: 20.543

4.  Lenalidomide-associated progressive multifocal leukoencephalopathy.

Authors:  Francesco Brigo; Elisabetta Pagani; Frediano Tezzon; Elisa Masi; Raffaele Nardone
Journal:  Leuk Lymphoma       Date:  2017-02-21

Review 5.  PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

Authors:  Joseph R Berger; Allen J Aksamit; David B Clifford; Larry Davis; Igor J Koralnik; James J Sejvar; Russell Bartt; Eugene O Major; Avindra Nath
Journal:  Neurology       Date:  2013-04-09       Impact factor: 9.910

6.  Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review.

Authors:  Elizabeth C Neil; Lisa M DeAngelis
Journal:  Blood Adv       Date:  2017-10-18

7.  Progressive multifocal leukoencephalopathy during ixazomib-based chemotherapy.

Authors:  C P Sawicki; S A Climans; C C Hsia; J A Fraser
Journal:  Curr Oncol       Date:  2018-02-28       Impact factor: 3.677

Review 8.  Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature.

Authors:  Divyanshu Dubey; Yinan Zhang; Donna Graves; Allen D DeSena; Elliot Frohman; Benjamin Greenberg
Journal:  Ther Adv Neurol Disord       Date:  2015-12-17       Impact factor: 6.570

9.  Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system.

Authors:  Dennis W Raisch; John A Rafi; Cheng Chen; Charles L Bennett
Journal:  Expert Opin Drug Saf       Date:  2016-06-20       Impact factor: 4.250

10.  Smoldering myeloma presenting as progressive multifocal leukoencephalopathy: a case report.

Authors:  Martina Troppmann; Roland Büttner; Michael Boewer; Bernd Salzberger
Journal:  J Med Case Rep       Date:  2012-07-02
View more
  2 in total

Review 1.  Progressive multifocal leukoencephalopathy in multiple myeloma. A literature review and lessons to learn.

Authors:  Ioannis Koutsavlis
Journal:  Ann Hematol       Date:  2020-10-03       Impact factor: 3.673

2.  Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma.

Authors:  Syeda Saba Kareem; Neena Viswanathan; Solmaz Sahebjam; Nam D Tran; Tyra Gatewood; Katherine Tobon; Rachid Baz; Yolanda Piña; Kenneth H Shain; Sepideh Mokhtari
Journal:  Onco Targets Ther       Date:  2022-09-06       Impact factor: 4.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.